128101-19-9

Basic information

• Product Name: 5-(4-FLUOROPHENYL)OXAZOLE
• Synonyms: 5-(4-FLUOROPHENYL)OXAZOLE;5-(4-Fluorophenyl)oxazole 97%;5-(4-Fluorophenyl)oxazole97%;5-(4-Fluorophenyl)-1,3-oxazole 97%;5-(4-Fluorophenyl)-1,3-oxazole97%
• CAS NO: 128101-19-9
• Molecular Formula: C₉H₆FNO
• Molecular Weight: 163.15
• Mol File: 128101-19-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 34 °C
• Boiling Point: 258.2 °C at 760 mmHg
• Flash Point: 110 °C
• Appearance: Brown to grey crystalline powder
• Density: 1.209 g/cm³
• Vapor Pressure: 0.0224mmHg at 25°C
• Refractive Index: 1.523
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(4-FLUOROPHENYL)OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-FLUOROPHENYL)OXAZOLE(128101-19-9)
• EPA Substance Registry System: 5-(4-FLUOROPHENYL)OXAZOLE(128101-19-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 128101-19-9(Hazardous Substances Data)

Usage

General Description

5-(4-Fluorophenyl)oxazole is a chemical compound with the molecular formula C9H6FNO. It is an oxazole derivative, which is a five-membered aromatic heterocycle with one oxygen and one nitrogen atom. The presence of the fluorophenyl group in the structure makes it an important building block in pharmaceutical and agrochemical synthesis. 5-(4-FLUOROPHENYL)OXAZOLE exhibits diverse biological activities, including antimicrobial, antitumor, and anti-inflammatory properties. It is also used as a fluorescent probe in biological imaging and as a ligand in coordination chemistry. Overall, 5-(4-Fluorophenyl)oxazole is a versatile chemical that finds application in various fields due to its unique structure and diverse properties.

InChI:InChI=1/C9H6FNO/c10-8-3-1-7(2-4-8)9-5-11-6-12-9/h1-6H

Upstream product

• 10564-55-3 1-isocyanatomethanesulfonyl-4-methyl-benzene 
• 459-57-4 4-fluorobenzaldehyde 
• 288-42-6 oxazol 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 2251-76-5 2-(4-fluorophenyl)-2-oxoacetic acid 
• 459-56-3 4-fluorobenzylic alcohol 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 459-46-1 4-Fluorobenzyl bromide 
• 29166-72-1 N,N,N′,N′-tetramethyl-N″-tert-butylguanidine 
• 87022-42-2 1-(isocyanomethyl)-1H-benzo[d][1,2,3]triazole 

Downstream Products

• 1060816-27-4 2-chloro-5-(4-fluorophenyl)oxazole 
• 159140-82-6 2,5-bis(4-fluorophenyl)oxazole 
• 1584688-12-9 C₁₄H₉FN₂O 
• 1584688-08-3 C₁₆H₁₂FNO 
• 1638125-50-4 C₁₆H₁₀FNO₂ 
• 1309868-07-2 2-(benzofuran-2-yl)-5-(4-fluorophenyl)-oxazole 

Relevant articles and documents

Orientation effects on C2(5)-C2?(5?) linked bioxazole isomers synthesized via regioselective and sequential C[sbnd]H arylation

Bis(4-fluorophenyl) substituted oxazole (2,5-Oxz) and C2(5)-C2?(5?) linked bioxazole isomers (C2-C2?_BOxz, C2-C5?_BOxz and C5-C5?_BOxz) were concisely synthesized via palladium-catalyzed regioselective and sequential C[sbnd]H arylation in 1–3 reaction steps along with 20%–83% of total yields from oxazole and 4-bromofluorobenzene. The linking orientation plays a key role in the packing geometry and photophysical properties of C2-C2'_BOxz, C2-C5'_BOxz and C5-C5'_BOxz. These bioxazole isomers in solid state showed significant differences in photoluminescence quantum yields (PLQY) (0.33, 0.25 and 0.04, respectively), delayed fluorescence properties and powder X-ray diffraction (PXRD) patterns, suggesting the divergence in intermolecular interactions. The theoretically calculated gradient isosurfaces and complexation energies indicate the existence of intense π-π interactions between molecular layers, which are in good agreement with the variation trend of optical properties.

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

MCR scaffolds get hotter with 18F-Labeling

Imaging techniques, such as positron emission tomography (PET), represent great progress in the clinical development of drugs and diagnostics. However, the efficient and timely synthesis of appropriately labeled compounds is a largely unsolved problem. Nu